According to the Zhitong Finance App, Tianjin Development (00882.HK) announced Lisheng Pharmaceutical's results for the nine months ended September 30, 2026, with total operating revenue of 888 million yuan, a year-on-year decrease of 11.84%; net profit attributable to owners of the parent company was 78.51 million yuan, a year-on-year decrease of 78.82%; and basic earnings per share were 0.25 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.